SUNLINK HEALTH SYSTEMS INC

CIK:0000096793|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Mar. 31, 2024
Net revenues	$ 7,323	$ 7,462	$ 23,181	$ 24,527
Costs and Expenses:
Salaries, wages and benefits	2,275	2,652	8,066	7,937
Supplies	30	36	104	109
Other operating expenses	717	589	2,354	2,279
Rent and lease expense	92	92	279	275
Depreciation and amortization	319	342	956	960
Operating Profit (Loss)	(683)	(853)	(2,889)	(1,736)
Other Income (Expense):
Gains (losses) on sale of assets	(14)	0	680	2
Impairment loss	0	0	(100)	0
Interest income, net	67	19	167	70
Loss from Continuing Operations before income taxes	(630)	(834)	(2,142)	(1,664)
Income Tax Benefit	0	(10)	0	(5)
Loss from Continuing Operations	(630)	(824)	(2,142)	(1,659)
Loss from Discontinued Operations, net of tax	(41)	(572)	(421)	(4,156)
Net Loss	(671)	(1,396)	(2,563)	(5,815)
Other comprehensive income	0	0	0	0
Comprehensive Loss	$ (671)	$ (1,396)	$ (2,563)	$ (5,815)
Continuing Operations:
Basic	$ (0.1)	$ (0.2)	$ (0.36)	$ (0.83)
Diluted	(0.1)	(0.2)	(0.36)	(0.83)
Discontinued Operations:
Basic	(0.01)	(0.08)	(0.06)	(0.59)
Diluted	(0.01)	(0.08)	(0.06)	(0.59)
Net Loss:
Basic	(0.09)	(0.12)	(0.3)	(0.24)
Diluted	$ (0.09)	$ (0.12)	$ (0.3)	$ (0.24)
Weighted-Average Common Shares Outstanding:
Basic	7,041	7,041	7,041	7,038
Diluted	7,041	7,041	7,041	7,038
Product [Member]
Costs and Expenses:
Cost of goods sold	$ 4,234	$ 4,339	$ 13,327	$ 13,871
Service [Member]
Costs and Expenses:
Cost of goods sold	$ 339	$ 265	$ 984	$ 832

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Statement of Cash Flows [Abstract]
Net Cash Used in Operating Activities	$ (2,543)	$ (2,592)
Cash Flows Provided by (Used in) Investing Activities:
Expenditures for property, plant and equipment - continuing operations	(558)	(1,089)
Expenditures for property, plant and equipment - discontinued operations	0	(91)
Proceeds from the sale of Trace - discontinued operations	0	500
Proceeds from sale of property, plant and equipment - continuing operations	501	5
Proceeds from sale of property, plant and equipment - discontinued operations	1,832	0
Proceeds from sale of investment in minority owned equity investment	1,064	0
Net Cash Provided by (Used in) Investing Activities	2,839	(675)
Cash Flows Provided by (Used in) Financing Activities:
Proceeds from share options exercises	0	6
Payments on long-term debt - discontinued operations	0	(14)
Net Cash Used in Financing Activities	0	(8)
Net Increase (Decrease) in Cash and Cash Equivalents	296	(3,275)
Cash and Cash Equivalents Beginning of Period	7,170	4,486
Cash and Cash Equivalents End of Period	7,466	1,211
Cash Paid (Received) for:
Interest	(167)	(70)
Income taxes	0	105
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	$ 391	$ 18

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Jun. 30, 2024
Current Assets:
Cash and cash equivalents	$ 7,466	$ 7,170
Receivables - net	2,940	3,371
Inventory	1,462	1,553
Current assets held for sale	0	1,959
Prepaid expense and other assets	1,837	1,611
Total current assets	13,705	15,664
Property, plant and equipment, at cost	11,047	12,683
Less accumulated depreciation	(9,151)	(9,874)
Property, plant and equipment - net	1,896	2,809
Noncurrent assets:
Intangible assets	1,180	1,180
Right of use assets	660	516
Other noncurrent assets	33	443
Total noncurrent assets	1,873	2,139
TOTAL ASSETS	17,474	20,612
Current Liabilities:
Accounts payable	1,473	1,905
Accrued payroll and related taxes	731	955
Current liabilities held for sale	0	0
Current operating lease liabilities	280	331
Other accrued expenses	1,017	1,022
Total current liabilities	3,501	4,213
Long-Term Liabilities
Noncurrent liability for professional liability risks	70	49
Long-term operating lease liabilities	388	197
Other noncurrent liabilities	105	180
Total long-term liabilities	563	426
Commitments and Contingencies
Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares	0	0
Common Shares, without par value: Issued and outstanding, 7,041 shares at September 30, 2024 and 7,041 at June 30, 2024	3,521	3,521
Additional paid-in capital	10,747	10,747
Retained earnings	(1,085)	1,478
Accumulated other comprehensive income	227	227
Total Shareholders’ Equity	13,410	15,973
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 17,474	$ 20,612